ArticleNephrology (Carlton, Vic.)2026
Burden of Chronic Kidney Disease in Asia From 1990 to 2023: A Global Burden of Disease Study 2023.
Article in Nephrology (Carlton, Vic.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimDespite growing recognition of chronic kidney disease (CKD) as a major health threat in Asia, its subregional variations are often overlooked. This study aimed to assess the CKD burden across five Asian subregions.
methodsThis study analysed data from the Global Burden of Disease Study 2023 to estimate the burden of CKD in Asia. CKD cases were classified using International Classification of Diseases codes. Age-standardized mortality rates (ASMRs) and age-standardized disability-adjusted life-year (DALY) rates (ASDRs) per 100 000 population were estimated from 1990 to 2023 across 34 Asian countries, which were grouped into five subregions: Central, East, South, Southeast Asia and high-income Asia Pacific. Estimates were stratified by age, sex and underlying causes and reported with 95% uncertainty intervals (UIs), along with an assessment of major risk factors.
resultsIn 2023, Southeast Asia experienced the heaviest CKD burden, with the highest ASMR (24.73 [95% UI, 19.98-29.83] per 100 000 population) and ASDR (816.37 [695.11-964.14]). Females under 35 years in South and Southeast Asia had a higher DALY burden than males. In Southeast Asia, type 1 diabetes contributed significantly to CKD deaths (ASMR, 3.18 [95% UI, 2.38-4.18] per 100 000 population), whereas CKD deaths in Central Asia were primarily due to other causes (7.48 [6.51-8.49]). High fasting plasma glucose levels were the leading risk factor across most regions, except in Central Asia.
conclusionAlthough CKD is often considered uniform in Asia, our findings reveal distinct subregional drivers. Effective CKD control requires a shift from aggregated targets to precision- and region-specific strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.